Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symp...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Cristina M. Merkhofer, MD, MHS, Christina S. Baik, MD, MPH
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2021-06-01
Serie:	JTO Clinical and Research Reports
Soggetti:	Pemetrexed EGFR mutation Non–small cell lung cancer Leptomeningeal disease Case report
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2666364321000369
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!